Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4644-4651
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4644
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4644
Table 2 Virologic and histologic efficacy at week 48 among treated patients with evaluable hepatic hepatitis B virus DNA pairs
| Week 48 efficacy (NC = M) | ETV (n = 159) | LAM (n = 146) |
| Serum HBV DNA, mean ± SE, change from baseline log10 IU/mL | -6.85 ± 0.16 | -5.30 ± 0.22 |
| Knodell necroinflammatory score, mean ± SE change from baseline | -3.4 ± 0.26 | -3.0 ± 0.29 |
| Ishak fibrosis score, mean ± SE change from baseline | -0.5 ± 0.08 | -0.3 ± 0.08 |
- Citation: Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651
- URL: https://www.wjgnet.com/1007-9327/full/v21/i15/4644.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i15.4644